ACR/ARHP Annual Meeting 2015
Ustekinumab Beneficial in Patients With Psoriatic Arthritis with Spondylitis and Peripheral Joint Involvement
Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.
